Premium
Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: A p hase 1, randomized controlled study
Author(s) -
Mann Donald,
Liu Jing,
Chew Marci L.,
Bockbrader Howard,
Alvey Christine W.,
Zegarac Elizabeth,
Pellock John,
Pitman Verne W.
Publication year - 2014
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.12830
Subject(s) - pregabalin , tolerability , medicine , pharmacokinetics , adverse effect , placebo , population , anesthesia , refractory (planetary science) , physics , alternative medicine , environmental health , pathology , astrobiology
Summary Objective To evaluate the safety, tolerability, and pharmacokinetics ( PK ) of pregabalin as adjunctive therapy in children with refractory partial seizures. Methods This was a phase 1, randomized, placebo‐controlled, parallel‐group, escalating‐dose, multiple‐dose study comprising a 7‐day, double‐blind treatment period and a single‐blind, single dose of pregabalin administered to all children on day 8. Children in four age cohorts (1–23 months, 2–6, 7–11, and 12–16 years) received one of four doses of pregabalin (2.5, 5, 10, or 15 mg/kg/day) or placebo. Safety and tolerability were assessed throughout the study. Steady‐state and single‐dose PK parameters on day 8 were analyzed using standard noncompartmental procedures. Results Sixty‐five children received at least one dose of treatment. Four pregabalin‐treated children discontinued treatment, three of whom received 15 mg/kg/day. Two children experienced serious adverse events, one of whom received pregabalin 15 mg/kg/day. During double‐blind treatment, the most common adverse events reported in the pregabalin‐treated population were somnolence (27.1%) and dizziness (12.5%). Steady‐state pregabalin peak and total exposure in each age cohort appeared to increase linearly with dose. Apparent oral clearance ( CL / F ) was directly related to creatinine clearance, consistent with adults. CL / F normalized for body weight was 43% higher in patients weighing <30 kg. Steady‐state and single‐dose PK were consistent. Significance Pregabalin at doses up to 10 mg/kg/day in children aged 1 month to 16 years, and at doses up to 15 mg/kg/day in those aged <6 years, demonstrated acceptable safety and tolerability. For children weighing <30 kg, a dose increase of 40% (mg/kg dosing) is required to achieve comparable exposure with adults or children weighing ≥30 kg. These data will inform dose selection in phase 3 trials of the efficacy and safety of adjunctive pregabalin in children with refractory partial seizures.